Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
Study Details
Study Description
Brief Summary
This phase I/II trial studies the side effects of glutaminase inhibitor CB-839 in combination with azacitidine in treating patients with myelodysplastic syndrome that has spread to other places in the body. Glutaminase inhibitor CB-839 and azacitidine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
PRIMARY OBJECTIVES:
- To determine the safety, tolerability and clinical activity of glutaminase inhibitor CB-839 (CB-839) in combination with azacitidine (AZA) for patients with advanced myelodysplastic syndrome (MDS).
SECONDARY OBJECTIVES:
- To explore the pharmacokinetics (PK) of CB-839 in combination with AZA. II. To explore the pharmacodynamics (PDn) of CB-839 in combination with AZA. III. To assess overall survival, event-free survival and duration of response of CB-839 in combination with AZA.
OUTLINE:
Patients receive glutaminase inhibitor CB-839 orally (PO) twice daily (BID) on days 1-28 and azacitidine subcutaneously (SC) or intravenously (IV) over 10-40 minutes on days 1-7.
After completion of study treatment, patients are followed up at 28 days.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Treatment (glutaminase inhibitor CB-839, azacitidine) Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28 and azacitidine SC or IV over 10-40 minutes on days 1-7. |
Drug: Azacitidine
Given IV or SC
Other Names:
Drug: Glutaminase Inhibitor CB-839
Given PO
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Incidence of adverse events Common Toxicity Criteria version 4.0 [Up to 4 years]
Safety data will be summarized using frequency and percentage, by category and severity.
Secondary Outcome Measures
- Rates of response (complete response + partial response) to therapy [Up to 4 years]
Will be estimated along with the 95% confidence interval.
- Event-free survival [Up to 4 years]
The Kaplan-Meier method will be used to estimate the probabilities. Log-rank tests will be used to compare among subgroups of patients.
- Overall survival [Up to 4 years]
The Kaplan-Meier method will be used to estimate the probabilities. Log-rank tests will be used to compare among subgroups of patients.
- Duration of response [Up to 4 years]
The Kaplan-Meier method will be used to estimate the probabilities. Log-rank tests will be used to compare among subgroups of patients.
- Anti-tumor activity [Up to 4 years]
Will be summarized graphically and with descriptive statistics.
- Pharmacodynamic markers [Up to 4 years]
Will be summarized graphically and with descriptive statistics.
- Exploratory biomarkers [Up to 4 years]
Will be summarized graphically and with descriptive statistics.
- Drug exposure levels [Up to 4 years]
Will be summarized graphically and with descriptive statistics.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed, informed consent must be obtained prior to any study specific procedures
-
Subjects with a histologically confirmed diagnosis of MDS, including both MDS and refractory anemia with excess blasts (RAEB)-T (acute myeloid leukemia [AML] with 20-30% blasts and multilineage dysplasia by French-American-British [FAB] criteria) by World Health Organization (WHO) and chronic myelomonocytic leukemia (CMML) are eligible
-
Subjects with high-risk MDS (i.e. International Prognostic Scoring System [IPSS] Intermediate-2 or high-risk; or R-IPSS high or very-high risk). Patients with Intermediate-1 risk by IPSS or Intermediate risk by R-IPSS and with IDH1 or IDH2, or high-risk molecular features including TP53, ASXL1, EZH2, and/or RUNX1 mutations are also eligible
-
Subjects with prior hypomethylating agent therapy exposure may be eligible based on discussion with the principal investigator (PI)
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
-
Serum bilirubin =< 2 x the upper limit of normal (ULN) (except for patients with Gilbert's disease)
-
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the laboratory ULN
-
Creatinine clearance > 30 mL/min based on the Cockcroft-Gault equation
-
Able to understand and voluntarily sign a written informed consent, and willing and able to comply with protocol requirements
-
Resolution of all treatment-related, non-hematological toxicities, except alopecia, from any previous cancer therapy to < grade 1 prior to the first dose of study treatment
-
Female patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days of the first dose of study drug and agree to use dual methods of contraception during the study and for a minimum of 3 months following the last dose of study drug. Post-menopausal females (>= 45 years old and without menses for >= 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for a minimum of 3 months following the last dose of study drug if sexually active with a female of childbearing potential
Exclusion Criteria:
-
Any prior or coexisting medical condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in the study
-
Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures
-
Active uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection
-
Clinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomy
-
Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement
-
Impaired cardiac function, uncontrolled cardiac arrhythmia, or clinically significant cardiac disease including the following: a) New York Heart Association grade III or IV congestive heart failure, b) myocardial infarction within the last 6 months
-
Subjects with a corrected QT (QTc) > 480 ms (QTc > 510 msec for subjects with a bundle branch block at baseline)
-
Nursing or pregnant women
-
Subjects with known hypersensitivity to study drugs or their excipients
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | M D Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Courtney DiNardo, M.D. Anderson Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 2016-0636
- NCI-2018-01243
- 2016-0636
- P30CA016672
- R01CA206210